Ilene Ceil Weitz, MD

Title(s)Professor of Clinical Medicine (Part-Time)
SchoolKeck School of Medicine of Usc
Address1441 Eastlake Ave.
Health Sciences Campus
Los Angeles CA 90033
Phone+1 323 865 3950
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Simmons College1971Academy Honor Society
    Alpha Omega Alpha1976Elected Member
    Cedars-Sinai Medical Center1987Morris Press Humanism Award
    Cedars-Sinai Medical Center1990Golden Apple Outstanding Physician Educator Award
    Division of Hematology, Keck School of Medicine1996Outstanding Voluntary Faculty

    Collapse Overview 
    Collapse Overview
    Dr. Ilene C. Weitz is an Associate Professor of Clinical Medicine at the Keck School of Medicine at the University of Southern California (USC). Her practice sites include, LAC+USC Medical Center, Keck Hospital of USC and USC Norris Cancer Hospital. Dr. Weitz is board certified in Internal Medicine and Hematology.

    Dr. Weitz earned her medical degree at Medical College of Pennsylvania in Philadelphia, followed by an internship and residency in internal medicine at Cedars-Sinai Medical Center. She conducted a fellowship in hematology/oncology at Scripps Clinic and Research Foundation in La Jolla, California.

    Dr. Weitz is a member of the Academy-Simmons College Honor Society, Alpha Omega Alpha, American Medical Womens Association, Los Angeles County Medical Women’s Association, Alumni Associations of Medical College of Pennsylvania and Cedars-Sinai Medical Center, American Society of Hematology, and American Society of Clinical Oncology. She received the Morris Press Humanism Award in 1987 and the “Golden Apple” Outstanding Physician Educator Award in 1990 from Cedars-Sinai Medical Center, as well as the Outstanding Voluntary Faculty Award in the Division of Hematology from USC School of Medicine. Dr Weitz has delivered nationwide lectures and has been published in numerous journals, including American Journal of Clinical Pathology, Hepatology, and Journal of Clinical Oncology, American Journal of Hematology.. She has also contributed eight book chapters or reviews.

    Dr. Weitz’ research and clinical interests include hematologic disorders such as anemias, thrombocytopenia and white blood cell disorders, paroxysmal nocgturnal hemoglobinurua (PNH), immune mediated anemias and thrombocytopenia, thrombosis and hemostasis.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study. Ann Hematol. 2024 Mar 23. Röth A, Barcellini W, Anderson Tvedt TH, Miyakawa Y, Kuter DJ, Su J, Jiang X, Hobbs W, Morales J, Shafer F, Weitz IC. PMID: 38519606.
      View in: PubMed   Mentions:    Fields:    
    2. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Adv. 2023 10 10; 7(19):5890-5897. Röth A, Broome CM, Barcellini W, Tvedt THA, Miyakawa Y, D'Sa S, Cella D, Bozzi S, Jayawardene D, Yoo R, Shafer F, Wardecki M, Weitz IC. PMID: 37459203; PMCID: PMC10558612.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP. Br J Haematol. 2023 10; 203(1):96-100. Weitz IC, Liebman HA. PMID: 37735550.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease. Am J Hematol. 2023 08; 98(8):1246-1253. Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Weitz IC, Yoo R, Jayawardene D, Vagge DS, Kralova K, Shafer F, Ward?cki M, Lee M, Berentsen S. PMID: 37246953.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH. J Blood Med. 2023; 14:239-245. Weitz IC. PMID: 37016661; PMCID: PMC10066888.
      View in: PubMed   Mentions: 1  
    6. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition. Blood Rev. 2023 05; 59:101041. Kulasekararaj AG, Kuter DJ, Griffin M, Weitz IC, Röth A. PMID: 36732204.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study. Eur J Haematol. 2023 Mar; 110(3):280-288. Röth A, Broome CM, Barcellini W, Jilma B, Hill QA, Cella D, Tvedt THA, Yamaguchi M, Lee M, Shafer F, Wardecki M, Jiang X, Patel P, Joly F, Weitz IC. PMID: 36403132.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022 Sep; 9(9):e648-e659. de Latour RP, Szer J, Weitz IC, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro CM, Nishimori H, Ajayi T, Al-Adhami M, Deschatelets P, Francois C, Grossi F, Risitano AM, Hillmen P. PMID: 36055332.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    9. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022 09 01; 140(9):980-991. Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardecki M, Shafer F, Lee M, Broome CM. PMID: 35687757; PMCID: PMC9437710.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    10. Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study. Ann Hematol. 2022 Oct; 101(10):2169-2177. Röth A, Barcellini W, Tvedt THA, Miyakawa Y, Kuter DJ, Su J, Jiang X, Hobbs W, Arias JM, Shafer F, Weitz IC. PMID: 35999387; PMCID: PMC9463238.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results. Haematologica. 2022 07 01; 107(7):1698-1702. Roth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Weitz IC, Patel P, Jiang X, Reuter C, Su J, Shafer F, Lee M, Berentsen S. PMID: 35172561; PMCID: PMC9244812.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    12. Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Front Immunol. 2021; 12:712572. Barratt J, Weitz I. PMID: 34566967; PMCID: PMC8458797.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    13. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021 03 18; 384(11):1028-1037. Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro C, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Ajayi T, Risitano A, Peffault de Latour R. PMID: 33730455.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    14. Acute ST-Segment Elevation Myocardial Infarction as Initial Presentation of Atypical Hemolytic-Uremic Syndrome. JACC Case Rep. 2021 Apr; 3(4):561-565. Chau E, Li S, Xu PZ, Li GX, Ghasem W, Weitz IC, DeClerck BK, DePasquale EC, Yaghmour B. PMID: 34317581; PMCID: PMC8302770.
      View in: PubMed   Mentions:
    15. Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series. Ann Hematol. 2021 Apr; 100(4):933-939. Martynova A, Chiu V, Mert M, Hermel D, Weitz IC. PMID: 33420879; PMCID: PMC7960622.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021 01 01; 106(1):230-237. Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H. PMID: 31949012; PMCID: PMC7776354.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    17. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. Hematology. 2020 Dec; 25(1):327-334. Tomazos I, Sierra JR, Johnston KM, Cheung A, Brodsky RA, Weitz IC. PMID: 32856539.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    18. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020 11; 95(11):1334-1343. de Castro C, Grossi F, Weitz IC, Maciejewski J, Sharma V, Roman E, Brodsky RA, Tan L, Di Casoli C, El Mehdi D, Deschatelets P, Francois C. PMID: 33464651; PMCID: PMC7693064.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    19. Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review. EJHaem. 2020 Jul; 1(1):44-50. Hermel M, Hermel D, Azam S, Shinbane J, Sarcon A, Jones E, Mehta A, Grazette L, Liebman H, Weitz I. PMID: 35847716; PMCID: PMC9175940.
      View in: PubMed   Mentions:
    20. Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. CNS Spectr. 2021 06; 26(3):195-196. Pittock SJ, Weitz I, Howard JF, Sabatella G, Mehta S, Franklin J. PMID: 32641193.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    21. Multidrug Therapy for Refractory Immune Thrombocytopenia in Pregnancy. Obstet Gynecol. 2020 03; 135(3):723-727. Chon AH, Chan R, Lee RH, Kwong K, Wertheimer FB, Weitz IC. PMID: 32028499.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia. Acta Haematol. 2020; 143(3):244-249. Piatek CI, Bocian H, Algaze S, Weitz IC, O'Connell C, Liebman HA. PMID: 31665725.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    23. Thrombotic Microangiopathy in Cancer. Semin Thromb Hemost. 2019 Jun; 45(4):348-353. Weitz IC. PMID: 31041804.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018 08 28; 2(16):2090-2094. Park MH, Caselman N, Ulmer S, Weitz IC. PMID: 30131343; PMCID: PMC6113612.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    25. Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center. Platelets. 2019; 30(3):413-417. O'Neill CM, Weitz IC, O'Connell C, Liebman HA. PMID: 29580123.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    26. Thrombotic microangiopathy in cancer. Thromb Res. 2018 04; 164 Suppl 1:S103-S105. Weitz IC. PMID: 29703465.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    27. Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients. Br J Haematol. 2018 10; 183(1):136-139. Weitz IC, Deloughery T. PMID: 28857126.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Autoimmune Hemolytic Anemia. Med Clin North Am. 2017 Mar; 101(2):351-359. Liebman HA, Weitz IC. PMID: 28189175.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    29. OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin. Thromb Res. 2016 Apr; 140 Suppl 1:S174. Piatek CI, Tagawa ST, Wei-Tsai D, Hanna D, Weitz IC, O'Connell C, Rochanda L, Groshen S, Liebman HA. PMID: 27161687.
      View in: PubMed   Mentions: 1     Fields:    
    30. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2015 Sep 10; 373(11):1032-9. Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, Weitz IC, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R. PMID: 26352814.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCTClinical Trials
    31. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015 Oct; 55(10):2398-403. Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA. PMID: 25989361.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    32. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. Ann Hematol. 2014 Nov; 93(11):1839-43. Aldoss I, Mark L, Vrona J, Ramezani L, Weitz I, Mohrbacher AM, Douer D. PMID: 24906216.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    33. Complement the hemostatic system: an intimate relationship. Thromb Res. 2014 May; 133 Suppl 2:S117-21. Weitz IC. PMID: 24862131.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    34. Atypical hemolytic uremic syndrome: the role of complement pathway gene mutation analysis. Clin Adv Hematol Oncol. 2014 Apr; 12(4):266-8. Weitz IC. PMID: 25003358.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. Blood Transfus. 2014 Jan; 12(1):111-3. Chaudhary P, Hepgur M, Sarkissian S, Smith RJ, Weitz IC. PMID: 24333077; PMCID: PMC3926711.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. Cytometry B Clin Cytom. 2014 May; 86(3):175-82. Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. PMID: 24227693; PMCID: PMC5594745.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    37. A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure. Cytometry B Clin Cytom. 2013 Oct 11. Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. PMID: 24127323.
      View in: PubMed   Mentions: 1     Fields:    
    38. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern Med J. 2013 Mar; 43(3):298-307. Weitz I, Meyers G, Lamy T, Cahn JY, Uranga MT, García Vela JA, Sanz MA, Severino B, Kelly RJ, Hillmen P, Hill A. PMID: 22909078.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    39. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion. Clin Adv Hematol Oncol. 2012 Nov; 10(11 Suppl 21):1-16. Szer J, Hill A, Weitz IC. PMID: 23271156.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012 Sep; 130(3):361-8. Weitz IC, Razavi P, Rochanda L, Zwicker J, Furie B, Manly D, Mackman N, Green R, Liebman HA. PMID: 22542362.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    41. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012 May; 28(5):789-96. Weitz I, Sanz MA, Henry D, Schipperus M, Godeau B, Northridge K, Gleeson M, Danese M, Deuson R. PMID: 22494019.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    42. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Semin Thromb Hemost. 2011 Apr; 37(3):315-21. Weitz IC. PMID: 21455865.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    43. Thrombosis in Paroxysmal Nocturnal Hemoglobinuria - insights into the role of complement in thrombosis. Thromb Res. 2010 Apr; 125 Suppl 2:S106-7. Weitz IC. PMID: 20433987.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    44. Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2009 Dec; 23(6):1239-49. Arkfeld DG, Weitz IC. PMID: 19932431.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    45. The role of oral anticoagulants in tumor biology. Semin Thromb Hemost. 2007 Oct; 33(7):695-8. Weitz IC, Liebman HA. PMID: 18000797.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    46. Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. J Clin Rheumatol. 2007 Apr; 13(2):89-91. Oliveira B, Arkfeld DG, Weitz IC, Shinada S, Ehresmann G. PMID: 17414538.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    47. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol. 2005 Feb; 78(2):138-41. Weitz IC. PMID: 15682410.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    48. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003 Jan; 72(1):43-52. Sutherland DE, Weitz IC, Liebman HA. PMID: 12508268.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    49. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. J Clin Oncol. 2000 Jan; 18(2):255-61. Presant CA, Wolf W, Waluch V, Wiseman CL, Weitz I, Shani J. PMID: 10637237.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    50. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 1997 May 15; 79(10):2024-7. Weitz IC, Israel VK, Liebman HA. PMID: 9149031.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    51. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology. 1993 Oct; 18(4):990-7. Weitz IC, Liebman HA. PMID: 8406374.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    52. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol. 1992 Nov; 98(5):534-41. Liebman HA, Carfagno MK, Weitz IC, Berard P, Diiorio JM, Vosburgh E, Simms RW. PMID: 1485607.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans